Compugen醫療 CGEN 深 滬
已收盤 07-02 16:00:00 美东时间
2.28
+0.150
+7.04%
華盛通- 最 高2.295
- 今 開2.12
- 成交量 49.50万股
- 最 低 2.12
- 昨 收 2.13
- 總市值 2.16亿
- 52周最高 3.235
- 市盈率 靜 6.05
- 換手率 0.52%
- 52周最低 1.295
- 委 比 55.22%
- 總股本 9458.46万
- 歷史最高 19.90
- 量 比 1.99
- 振 幅 8.22%
- 歷史最低 0.51
- 每 手 1
- 風險率 0.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Compugen To Present Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701, Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-c...
06-11 19:14
Compugen Q1 2026 Earnings Call: Complete Transcript
On Monday, Compugen (NASDAQ:CGEN) discussed first-quarter financial results dur...
06-01 21:04
美股大行评级 | 英伟达绩后获11家大行集体上调目标价；劳氏、ELF、Intuit、VF等惨遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx药业"超配"评级，目标价从84美元升至96美元；Ascendiant Capital：维持Liqtech国际"买入"评级，目标价从4.3美元升至4.4美元
05-22 10:18
Leerink Partners Maintains Outperform on Compugen, Lowers Price Target to $5
Leerink Partners maintains Compugen (NASDAQ:CGEN) with a Outperform and lowers the price target from $13 to $5.
05-21 22:38
Earnings Scheduled For May 18, 2026
Companies Reporting Before The Bell • Compugen (NASDAQ:CGEN) is likely to repor...
05-18 19:11
Compugen Q1 EPS $(0.08) Misses $(0.07) Estimate, Sales $2.176M Beat $2.095M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is unchanged from the same period last year. The company reported
05-18 19:01
Compugen Reports First Quarter 2026 Results
COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027 Partner AstraZeneca is advancing rilvego...
05-18 19:00
Compugen Q1 2026 Earnings Preview
Compugen (CGEN) is scheduled to announce Q1 earnings results on Monday, May 18th, after market close. The consensus EPS Estimate is -$0.08 (flat Y/Y) and the consensus Revenue Estimate is $1.26M (-45....
05-18 05:35
Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
HOLON, Israel, May 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by...
05-12 19:00
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
HOLON, Israel, April 9, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today an...
04-09 19:00
